Ralliant Corporation $RAL Stock Position Lifted by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Ralliant Corporation (NYSE:RAL) by 546.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 468,704 shares of the company’s stock after purchasing an additional 396,178 shares during the quarter. SG Americas Securities LLC’s holdings in Ralliant were worth $19,493,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Danske Bank A S bought a new position in Ralliant in the 4th quarter valued at about $25,000. Allworth Financial LP raised its position in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Ralliant during the 4th quarter worth about $26,000. Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the 3rd quarter worth approximately $26,000. Finally, Rothschild Investment LLC boosted its holdings in shares of Ralliant by 98.1% in the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently commented on RAL shares. Wall Street Zen upgraded shares of Ralliant from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Morgan Stanley lifted their price target on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday. Evercore assumed coverage on Ralliant in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price objective on the stock. Finally, Truist Financial restated a “buy” rating and issued a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $69.00.

Ralliant Stock Up 1.9%

RAL stock opened at $73.58 on Friday. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $75.41. The firm has a market cap of $8.24 billion and a PE ratio of -6.73. The firm has a 50 day simple moving average of $57.60 and a 200 day simple moving average of $51.10. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The firm had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.